Skip to main content

Table 1 Inclusion and exclusion criteria

From: Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy

Inclusion criteria Exclusion criteria
Age between 20 and 75 years History of kidney transplantation
Type 2 diabetes using a glucose-lowering agent or insulin Advanced congestive heart failure (≥ NYHA class III)
Estimated GFR by the IDMS MDRD equation ≥30 ml/min/1.73 m2 Uncontrolled arrhythmia
More than two UACR ≥30 mg/g or UPCR ≥ 300 mg/g in the most recent 6 months Advanced liver cirrhosis (Child-Pugh class C)
Blood pressure ≤140/90 mmHg without any additional antihypertensive medications in the most recent 3 months History of bleeding diathesis
  Active infection or uncontrolled inflammatory disorders
  History of cerebrovascular accident or myocardial infarction
  Current use of an anticoagulant
  Current use of more than two antiplatelet agents
  Advanced malignancy (life expectancy ≤6 months)
  Uncontrolled diabetes (HbA1C >10%)
  Severe anemia (hemoglobin <8.0 g/dL)
  Pregnancy or lactation
  Genetic disease including galactose intolerance, lactose deficiency, and glucose-galactose malabsorption
  1. GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; IDMS, isotope dilution mass spectrometry; MDRD, Modification of Diet in Renal Disease; NYHA, New York Heart Association; UACR, urine albumin to creatinine ratio; UPCR, urine protein to creatinine ratio.